Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

DOI: 10.3390/cancers11010124

Keywords: anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), tumor protein p53 gene (TP53) mutation, tyrosine kinase inhibitor, progression-free survival, overall survival

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text